Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313408063> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4313408063 endingPage "176.14" @default.
- W4313408063 startingPage "176.14" @default.
- W4313408063 abstract "Abstract Epithelial ovarian cancer (OC) is the most lethal gynecological malignancy. While OC is an immunogenic tumor, single-agent anti-PD-1 have limited efficacy in recurrent OC. Blockade of the CD47/SIRPα pathway, a phagocytosis checkpoint in macrophages and other myeloid cells, can enhance myeloid-driven antitumor immunity and tumor control. However, the benefit of targeting CD47/SIRPα in recurrent OC has been limited. Prior work from our lab and others point to complement priming of innate immune responses as a barrier to T-cell-driven anti-tumor immunity. However, in the specific context of anti-CD47 therapy, complement opsonization of tumor cells could augment the capacity of myeloid cells to phagocytose or injure tumor cells. The role of complement deficiency with anti-CD47 therapy in tumor control is a gap in the field, we therefore evaluated the efficacy of anti-CD47 in female wild-type (WT) versus C3−/− and C5aR1−/− with syngeneic OC (ID8). Mice (n=8–10 per group) were administered IP ID8 tumor cells followed by anti-CD47 or isotype twice weekly for 3 weeks and were monitored for the ascites development and survival. On day 84, all WT mice treated with isotype had ascites by visual inspection and 3 of 10 died. The proportion of mice with ascites varied in other groups, C3−/− mice treated with anti-CD47 having the lowest proportion, 4 of 9 mice with ascites and no deaths (Fisher’s test, WT-isotype vs C3−/− + anti-CD47, p= 0.01). A limitation is the potential endogenous complement production by tumor cells, which will be evaluated. These results suggest a potential benefit for dual targeting of the CD47/SIRPα and complement pathways in OC. Additional studies will probe immunologic correlates and survival benefits of these therapies in OC. This work was supported by Roswell Park Cancer Center Support Grant P30CA016056 and Apellis Pharmaceuticals, Inc" @default.
- W4313408063 created "2023-01-06" @default.
- W4313408063 creator A5007029038 @default.
- W4313408063 creator A5016454018 @default.
- W4313408063 creator A5034560158 @default.
- W4313408063 creator A5037238797 @default.
- W4313408063 creator A5045720848 @default.
- W4313408063 creator A5052175895 @default.
- W4313408063 creator A5059770078 @default.
- W4313408063 creator A5072224019 @default.
- W4313408063 creator A5073615852 @default.
- W4313408063 creator A5083442370 @default.
- W4313408063 date "2022-05-01" @default.
- W4313408063 modified "2023-10-16" @default.
- W4313408063 title "Complement C3 deficiency enhances anti-CD47 efficacy in murine ovarian cancer model." @default.
- W4313408063 doi "https://doi.org/10.4049/jimmunol.208.supp.176.14" @default.
- W4313408063 hasPublicationYear "2022" @default.
- W4313408063 type Work @default.
- W4313408063 citedByCount "0" @default.
- W4313408063 crossrefType "journal-article" @default.
- W4313408063 hasAuthorship W4313408063A5007029038 @default.
- W4313408063 hasAuthorship W4313408063A5016454018 @default.
- W4313408063 hasAuthorship W4313408063A5034560158 @default.
- W4313408063 hasAuthorship W4313408063A5037238797 @default.
- W4313408063 hasAuthorship W4313408063A5045720848 @default.
- W4313408063 hasAuthorship W4313408063A5052175895 @default.
- W4313408063 hasAuthorship W4313408063A5059770078 @default.
- W4313408063 hasAuthorship W4313408063A5072224019 @default.
- W4313408063 hasAuthorship W4313408063A5073615852 @default.
- W4313408063 hasAuthorship W4313408063A5083442370 @default.
- W4313408063 hasConcept C121608353 @default.
- W4313408063 hasConcept C126322002 @default.
- W4313408063 hasConcept C160448771 @default.
- W4313408063 hasConcept C168507396 @default.
- W4313408063 hasConcept C203014093 @default.
- W4313408063 hasConcept C2780104668 @default.
- W4313408063 hasConcept C2780427987 @default.
- W4313408063 hasConcept C502942594 @default.
- W4313408063 hasConcept C71924100 @default.
- W4313408063 hasConcept C86803240 @default.
- W4313408063 hasConcept C8891405 @default.
- W4313408063 hasConcept C89372155 @default.
- W4313408063 hasConceptScore W4313408063C121608353 @default.
- W4313408063 hasConceptScore W4313408063C126322002 @default.
- W4313408063 hasConceptScore W4313408063C160448771 @default.
- W4313408063 hasConceptScore W4313408063C168507396 @default.
- W4313408063 hasConceptScore W4313408063C203014093 @default.
- W4313408063 hasConceptScore W4313408063C2780104668 @default.
- W4313408063 hasConceptScore W4313408063C2780427987 @default.
- W4313408063 hasConceptScore W4313408063C502942594 @default.
- W4313408063 hasConceptScore W4313408063C71924100 @default.
- W4313408063 hasConceptScore W4313408063C86803240 @default.
- W4313408063 hasConceptScore W4313408063C8891405 @default.
- W4313408063 hasConceptScore W4313408063C89372155 @default.
- W4313408063 hasIssue "1_Supplement" @default.
- W4313408063 hasLocation W43134080631 @default.
- W4313408063 hasOpenAccess W4313408063 @default.
- W4313408063 hasPrimaryLocation W43134080631 @default.
- W4313408063 hasRelatedWork W1593627335 @default.
- W4313408063 hasRelatedWork W1966649467 @default.
- W4313408063 hasRelatedWork W1975327241 @default.
- W4313408063 hasRelatedWork W2012647730 @default.
- W4313408063 hasRelatedWork W2080803812 @default.
- W4313408063 hasRelatedWork W2141965224 @default.
- W4313408063 hasRelatedWork W4223564623 @default.
- W4313408063 hasRelatedWork W4362543828 @default.
- W4313408063 hasRelatedWork W4366823306 @default.
- W4313408063 hasRelatedWork W883946336 @default.
- W4313408063 hasVolume "208" @default.
- W4313408063 isParatext "false" @default.
- W4313408063 isRetracted "false" @default.
- W4313408063 workType "article" @default.